MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Multidrug therapy

  • Home
  • Multidrug therapy
新規診断の Mycobacterium avium complex 肺疾患に対する Amikacin Liposome Inhalation Suspension：第3b相 ENCORE試験
Posted inInfectious Diseases news Respiratory

Amikacin Liposome Inhalation Suspension in Newly Diagnosed Mycobacterium avium Complex Lung Disease: Phase 3b ENCORE Trial

Posted by By MedXY 10/17/2026
The ENCORE trial demonstrates that amikacin liposome inhalation suspension combined with multidrug therapy improves respiratory symptoms and culture conversion in newly diagnosed Mycobacterium avium complex lung disease patients.
Read More
  • Assessing Muscle Recovery: Responsiveness of the K-Force Grip Dynamometer in ICU-Acquired Weakness Patients
  • Long-Acting Injectable Cabotegravir-Rilpivirine Every 8 Weeks for Adolescents with HIV in Sub-Saharan Africa: Evidence from the LATA Trial and Contemporary Context
  • Optimizing Antibiotic Therapy for Community-Acquired Pneumonia in Children with Medical Complexity: Evidence for Narrow-Spectrum Use
  • Phenotype-Specific Mosaic Chromosomal Alterations in Systemic Sclerosis: Implications for Disease Subtypes and Clinical Outcomes
  • Impact of Donor Warm Ischemic Time on Biliary Complications After Laparoscopic Donor Right Hepatectomy: Insights From a Retrospective Cohort Study
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification semaglutide SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top